NasdaqGM:NTLABiotechs
ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In Focus
ARK Invest recently acquired over 3 million Intellia Therapeutics shares, worth more than US$43 million.
The purchase reflects increased institutional interest in Intellia Therapeutics, which trades under ticker NasdaqGM:NTLA.
This transaction follows earlier coverage that focused on Intellia's clinical programs, regulatory updates, and financial position.
Intellia Therapeutics focuses on CRISPR/Cas9-based therapeutics, an area that many investors watch closely as gene editing moves from...